SANOFI INDIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,246 INR | -1.52% |
|
-0.95% | +2.22% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 32.69 and 30.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.22% | 2.31B | - | ||
| +20.83% | 43.57B | B- | ||
| +20.70% | 22.7B | B+ | ||
| +16.41% | 14.32B | - | ||
| +11.11% | 13.42B | B+ | ||
| +45.91% | 11.83B | B | ||
| -8.84% | 6.98B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +12.33% | 5.51B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- SANOFI Stock
- SANOFI Stock
- Ratings Sanofi India Limited
